Diabetes Drug Development: Post-Avandia
This article was originally published in RPM Report
There are new considerations for developing diabetes drugs when it comes to FDA's expectations. Here are some of the questions to consider.
You may also be interested in...
The Victoza approval took longer than Novo hoped. But the review time looks like nothing compared to the post-marketing monitoring the company will be required to do.
Former MedImmune CEO David Mott discusses the key regulatory and reimbursement risks in drug development. While he sees plenty of venture capitalist money for truly innovative products, there are several areas he tends to avoid at all costs: vaccines, antibiotics, diabetes and-over the longer term-oncology drug development.
In Part II of The RPM Report’s roundtable discussion with three top FDA officials, the importance and implementation of FDA’s new REMS authorities, drug withdrawal precedents and the agency’s view of outcomes studies are the focus of the discussion.